Chirag PatelCo-Chief Executive Officer and President

Mr. Patel was Amneal’s Co-Founder and served as Co-Chairman and Co-Chief Executive Officer from 2002 to the completion of the combination with Impax Laboratories, Inc. in 2018. He served as a Co-Chairman of the Company’s Board since the combination. With his brother, Chintu Patel, Mr. Patel has also invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv Biosciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Earlier in his career, Mr. Patel co-founded technology companies NextGen Technologies and Veriprise Wireless. Mr. Patel also serves on the boards of the Liberty Science Center of New Jersey, New Jersey City University, Art of Living Foundation, Family Reach Foundation, and WIN Foundation, and is a recipient of the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award®. Mr. Patel supports various philanthropic causes. Mr. Patel, together with his wife, Priti Patel, established the Niswarth International Foundation in 2013, which aims to bring fresh water, sanitation, nutrition and education to underprivileged children. Mr. Patel received his bachelor’s degrees in Commerce from H.A. College of Commerce, India, and in Business Administration from New Jersey City University. He also holds an honorary Doctorate of Humane Letters from New Jersey City University in recognition of his efforts to serve others.

Chintu PatelCo-Chief Executive Officer

Mr. Patel, R.Ph. most recently served as the Chief Executive Officer of Kashiv BioSciences and was Amneal’s Co-Founder and served as Co-Chairman of Amneal from 2002 to the completion of the combination with Impax Laboratories, Inc. in 2018. He served as a Co-Chairman of the Company’s Board since the combination. With his brother, Chirag Patel, Mr. Patel also co-founded and invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv BioSciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Before founding Amneal, Mr. Patel was a pharmacist and senior-level manager with Eckerd Pharmacy from 1994 to 2002, where he won numerous awards. Mr. Patel has been a featured speaker at the Hauppauge Industrial Association in New York and serves on the boards of the Long Island Association, Long Island University, and the Make-a-Wish Foundation®, and is a recipient of the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award®. Mr. Patel and his wife, Falguni Patel, run the Irada International Foundation, which focuses on health, education, and community outreach projects in India and the United States. Mr. Patel holds a bachelor’s degree in Pharmacy from Rutgers College of Pharmacy.

Andrew S. BoyerExecutive Vice President, Commercial Operations

Andy most recently served as President and CEO of North America Generics, Teva Pharmaceuticals, Inc.  Prior to joining Teva, Andy was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan plc (formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.) since September 2006. He joined then Watson in 1998 as Associate Director of Marketing in Generics. Before joining Watson, Andy served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Andy received his Bachelor’s degree in Business Administration and Management from State University of New York at Albany.

Todd P. BranningSenior Vice President, Chief Financial Officer

Todd is responsible for leading Amneal’s global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Corporate Communications, and Information Technology. He brings more than 25 years of experience leading the finance and accounting strategies as well as corporate financial planning and analysis (FP&A) for public companies, primarily in the pharmaceuticals sector. Most recently, he served as Senior Vice President, Chief Financial Officer, for Teva Pharmaceuticals’ multi-billion-dollar Global Generic Medicines division. As CFO of Teva Pharmaceuticals’ Global Generic Medicines division, Mr. Branning led the finance function, served on the leadership team responsible for managing the day-to-day operations of Teva’s largest commercial unit and collaborated closely with Investor Relations, Treasury and Information Technology. Prior to joining Teva in 2016, he served as Vice President, Finance, for Allergan plc. Mr. Branning has also served in financial leadership roles at PricewaterhouseCoopers, PPG Industries, Inc. and Merck & Co., Inc. Mr. Branning holds an MBA degree from Carnegie Mellon University and a BBA from the University of Miami. He is a Certified Public Accountant and has completed a CFO certification program from The Wharton School at the University of Pennsylvania.

David A. BuchenSenior Vice President, Chief Legal Officer and Corporate Secretary

David is responsible for leading Amneal’s global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company’s corporate legal strategies to drive Amneal’s continued growth. He brings more than 25 years of experience in the pharmaceutical industry, with notable expertise driving corporate value creation through world-class legal strategies supporting corporate securities, IP, anti-trust, employment, litigation and Mergers & Acquisitions (M&A). Most recently, David served as a consultant to the pharmaceutical industry, providing counsel to various global and U.S. manufacturing, marketing and distribution companies. Prior to establishing his consultancy, he held several executive leadership roles, including serving as EVP – Commercial, North American Generics and International as well as 12 years as Chief Legal Officer and Corporate Secretary supporting Watson Pharmaceuticals’ growth and transformation from a US-focused $500 million generic pharmaceutical company to a $16 billion global specialty leader rebranded as Actavis, plc. David holds a Bachelor of Arts degree from the University of California at Berkeley and a Juris Doctor degree from the George Washington University Law School. He has been recognized by the National Law Journal as one of the Top 50 General Counsels in the U.S.

Joseph GreerSenior Vice President, Global Quality Management

Joe is responsible for leading quality management globally and has more than 27 years of quality and regulatory experience in positions with G&W Labs, Perrigo, KVD Pharma, Pliva, Barr Laboratories, and Novartis Pharmaceuticals.  Joe is an active member of various industry organizations, including the American Chemical Society, Regulatory Affairs Professionals Society and the American Society for Quality.  He holds bachelor’s degrees in chemistry and biology from Washington & Jefferson College in Washington, Pennsylvania, and a master’s degree in regulatory affairs and quality assurance at Temple University, School of Pharmacy in Pennsylvania.

Pradeep BhadauriaChief Scientific Officer

Pradeep oversees Global Research & Development, Clinical Affairs and Regulatory Affairs and is responsible for driving the growth of our generics and specialty pipeline. He has more than 20 years of experience leading the development capabilities for several leading generic and specialty pharmaceutical companies. Throughout his career, his leadership has resulted in the development and filing of more than 200 products, including numerous first-to-file and first-to-market opportunities. Pradeep has deep expertise across nearly all dosage forms and demonstrated strength in helping companies diversify their pipelines and portfolios through complex generics, 505(B) 2s, investigational new drugs and new drug applications. Prior to joining Amneal, he served as Executive Vice President, Global R&D for Apotex, Inc., responsible for leading the company’s entire global R&D activities. He also managed a large generic R&D portfolio across many dosage forms for various global markets. Prior to joining Apotex, he served as Vice President – Generic R&D for Allergan/Actavis. Pradeep holds a Master of Pharmacy (M.Pharm) from the Birla Institute of Technology in India and a Bachelor of Pharmacy from SGSITS, Devi Ahilya University in India. He also holds several patents and has published research in various publications.

Sanjay JainPresident • India

Sanjay has oversight for all aspects of Amneal India operations, including managing the overall productivity and quality deliverables. He has extensive experience managing Operations, Validation and Quality, as well as Regulatory audits originating from the USFDA, MHRA, EU, TGA, Anvisa, MCC and Health Canada. Prior to joining Amneal, Sanjay held Quality and Operations positions at Ranbaxy Laboratories, Zydus Cadila, Torrent Pharmaceuticals, Cadila Pharmaceuticals, Intas Pharmaceuticals, Bharat Parenterals and Mesco Pharmaceuticals. He has developed quality systems, implemented various process improvement projects, developed and audited API vendor sites across the globe and successfully faced regulatory audits of various regulatory agencies multiple times. He is a member of the International Society for Pharmaceutical Engineering (ISPE) and Parenteral Drug Association (PDA and an accomplished speaker at various international conferences. He holds an undergraduate degree in Pharmacy and a graduate degree in Quality Management.

Nikita ShahSenior Vice President, Chief Human Resources Officer

Nikita oversees human resources for Amneal.  Prior to joining Amneal, Nikita led the internal audit and human resources functions for Warner Chilcott, a global specialty pharmaceutical company. She also supported corporate M&A, process improvements and systems efficiencies across the organization. Prior to Warner Chilcott, Nikita held roles of increasing responsibilities at AT&T and Deloitte Consulting.  Nikita received her master’s degrees in accounting and auditing from Gujarat University, India. She is a certified public accountant.

Joseph TodiscoSenior Vice President, Specialty Commercial

Joe has leadership responsibility for Specialty and International, as well as continued responsibility for the Amneal-Impax integration process. Joe joined Amneal six years ago as the head of Corporate Development and has been an integral part of the management team that executed the Amneal-Impax business combination, as well as multiple other business development, licensing and M&A transactions.  In addition to his role in Corporate Development, Joe held management oversight responsibility for Gemini Laboratories, building the company from inception to a highly profitable specialty pharmaceutical platform. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy’s North American Commercial Strategy and Business Development, and held various leadership roles with Par Pharmaceuticals. Prior to working in the pharmaceutical industry, Joe was an investment banker for Oppenheimer & Co. and also worked in financial services for Marsh & McLennan Companies.  Joe holds a bachelor’s degree in Economics from Georgetown University in Washington D.C. and an M.B.A. from Fordham Graduate School of Business in New York.